Health · 8 views
Ziltivekimab Falls Short for Cutting Cardiovascular Events in ASCVD, CKD
(MedPage Today) -- Despite lowering inflammatory markers, treatment with the monoclonal antibody ziltivekimab did not reduce cardiovascular events in patients with atherosclerotic cardiovascular disease (ASCVD), chronic kidney disease…
AI Summary
Treatment with the monoclonal antibody ziltivekimab lowered inflammatory markers in patients who have both atherosclerotic cardiovascular disease and chronic kidney disease. However, the therapy failed to reduce cardiovascular events in this population.
AI summaries can be wrong sometimes—always verify important details using the source article.
How AI & Automation are usedCoverage Context
More from Health
Continue reading recent Health coverage
- Financial incentives nearly double quit rates among underserved people who smoke in national studyContinue reading
- Oral LSD Drug Hits Phase III Endpoints in Anxiety, DepressionContinue reading
- Lowering blood pressure after stroke or with diabetes poses challenges, in research and practiceContinue reading
- Potential driver of severe early-onset preeclampsia identifiedContinue reading
Support HappeningNow
Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.
Support HappeningNow